Dosimetric Improvements Utilising Intensity Modulated Radiation
Therapy for Patients with Glioblastoma Multiforme
24
352, No. 10, 2005, pp. 987-996.
http://dx.doi.org/10.1056/NEJMoa043330
[2] R. Stupp, M. E. Hegi, W. P. Mason, et al., “Effects of Ra-
diotherapy with Concomitant and Adjuvant Temozolo-
mide versus Radiotherapy Alone on Survival in Glioblas-
toma in a Randomised Phase III Study: 5-Year Analysis
of the EORTC-NCIC Trial,” Lancet Oncology, Vol. 10,
No. 5, 2009, pp. 459-466.
http://dx.doi.org/10.1016/S1470-2045(09)70025-7
[3] P. Brown, M. Maurer, T. Rummans, et al., “A Prospec-
tive Study of Quality of Life in Adults with Newly Diag-
nosed High-Grade Gliomas: The Impact of the Extent of
Resection on Quality of Life and Survival,” Neurosurgery,
Vol. 57, No. 3, 2005, pp. 495-504.
http://dx.doi.org/10.1227/01.NEU.0000170562.25335.C7
[4] S. L. Wolden, W. C. Chen, D. G. Pfister, et al., “Intensity-
Modulated Radiation Therapy (IMRT) for Nasopharynx
Cancer: Update of the Memorial Sloan-Kettering Experi-
ence,” International Journal of Radiation Oncology Bi-
ology Physics, Vol. 64, No. 1, 2006, pp. 57-62.
http://dx.doi.org/10.1016/j.ijrobp.2005.03.057
[5] A. Pollack, A. Hanlon, E. M. Horwitz, et al., “Radiation
Therapy Dose Escalation for Prostate Cancer: A Ration-
ale for IMRT,” World Journal of Urology, Vol. 21, No. 4,
2003, pp. 200-208.
http://dx.doi.org/10.1007/s00345-003-0356-x
[6] M. Back, T. Eade, M. Kastelan, et al., “Progress in Multi-
disciplinary Management of Glioblastoma Multiforme
Translating to Improvement in Median Survival,” APJCO,
Vol. 7, No. S4, 2011, p. 112.
[7] M. Klein, J. J. Heiman s, N. K. Aaronson, et al., “Effe ct of
Radiotherapy and Other Treatment-Related Factors on
Mid-Term to Long-Term Cognitive Sequelae in Low-
Grade Gliomas: A Comparative Study,” Lancet, Vol. 360,
No. 9343, 2002, pp. 1361-1268.
http://dx.doi.org/10.1016/S0140-6736(02)11398-5
[8] R. Henriksson, A. Bottomley, W. Mason, et al., “Progres-
sion-Free Survival (PFS) and Health-Related Quality of
Life (HRQoL) in AVAglio, a Phase III Study of Bevaci-
zumab, Temoz olomide , and Ra diotherapy in Newly Diag-
nosed Glioblastoma (GBM),” Journal of Clinical Oncol-
ogy, Vol. 31, 2013.
[9] R. Stupp, M. E. Hegi, B. Neyns, et al., “Phase I/IIa Study
of Cilengitide and Temozolomide with Concomitant Ra-
diotherapy Followed by Cilengitide and Temozolomide
Maintenance Therapy in Patients with Newly Diagnosed
Glioblastoma,” Journal of Clinical Oncology, Vol. 28, No.
16, 2010, pp. 2712-2718.
http://dx.doi.org/10.1200/JCO.2009.26.6650
[10] M. Gilbert, J. Dignam, M. Won, et al., “RTOG 0825:
Phase III Double-Blind Placebo-Controlled Trial Evalu-
ating Bevacizumab in Patients with Newly Diagnosed
Glioblastoma,” Journal of Clinical Oncology, Vol. 31,
2013.
[11] D. Amelio, S. Lorentini, M. Schwartz and M. Amichetti,
“Intensity-Modulated Radiation Therapy in Newly Diag-
nosed Glioblastoma. A Systematic Review on Clinical
and Technical Issues,” Radiotherapy Oncology, Vol. 97,
No. 3, 2010, pp. 361-369.
http://dx.doi.org/10.1016/j.radonc.2010.08.018
[12] R. Cardinale, M. Won, A. Choucair, et al., “A Phase II
Trial of Accelerated Radiotherapy Using Weekly Stereo-
tactic Conformal Boost for Supratentorial Glioblastoma
Multiforme: RTOG 0023,” International Journal of Ra-
diation Oncology Biology Physics, Vol. 65, No. 5, 2006,
pp. 1422-1428.
http://dx.doi.org/10.1016/j.ijrobp.2006.02.042
[13] L. Souhami, W. Seiferheld, D. Brachman, et al., “Rando-
mized Comparison of Stereotactic Radiosurgery Followed
by Conventional Radiotherapy with Carmustine to Con-
ventional Radiotherapy with Carmustine for Patients with
Glioblastoma Multiforme: Report of Radiation Therapy
Oncology Group 93-05 Protocol,” International Journal
of Radiation Oncology Biology Physics, Vol. 60, No. 3,
2004, pp. 853-860.
http://dx.doi.org/10.1016/j.ijrobp.2004.04.011
[14] N. J. Laperriere, P. M. Leung, S. McKenzie, et al., “Ran-
domized Study of Brachytherapy in the Initial Manage-
ment of Patients with Malignant Astrocytoma,” Interna-
tional Journal of Radiation Oncology Biology Physics,
Vol. 41, No. 5, 1998, pp. 1005-1011.
http://dx.doi.org/10.1016/S0360-3016(98)00159-X
[15] M. D. Piroth, M. Pinkawa, R. Holy, et al., “Integrated
Boost IMRT with FET-PET-Adapted Local Dose Escala-
tion in Glioblastomas. Results of a Prospective Phase II
Study,” Strahlentherapy Onkology, Vol. 188, No. 4, 2012,
pp. 334-339.
http://dx.doi.org/10.1007/s00066-011-0060-5
[16] M. Massaccesi, M. Ferro, S. Cilla, et al., “Accelerated
Intensity-Modulated Radiotherapy plus Temozolomide in
Patients with Glioblastoma: A Phase I Dose-Escalation
Study (ISIDE-BT1),” International Journal of Clinical
Oncology, 2012.
[17] K. Reddy, D. Damek, L. E. Gaspar, et al., “Phase II Trial
of Hypofractionated IMRT with Temozolomide for Pa-
tients with Newly Diagnosed Glioblastoma Multiforme,”
International Journal of Radiation Oncology Biology
Physics, Vol. 84, No. 3, 2012, pp. 655-660.
http://dx.doi.org/10.1016/j.ijrobp.2012.01.035
[18] M. Matsuo, K. Miwa, O. Tanaka, et al., “Impact of
[11C]Methionine Positron Emission Tomography for Tar-
get Definition of Glioblastoma Multiforme in Radiation
Therapy Planning,” International Journal of Radiation
Oncology Biology Physics, Vol. 82, No. 1, 2012, pp. 83-
89. http://dx.doi.org/10.1016/j.ijrobp.2010.09.020
Open Access JCT